Related Experiment Videos
Cost effectiveness of surfactant replacement in preterm babies
Insights
Surfactant therapy for premature infants with respiratory distress syndrome (RDS) improves survival but increases costs. Cost-effectiveness analysis suggests it is beneficial for the smallest babies, though optimal policies for larger infants require further study.
Area of Science:
- Neonatal Medicine
- Health Economics
- Respiratory Physiology
Background:
- Surfactant replacement therapy is an established treatment for respiratory distress syndrome (RDS) in preterm infants.
- This therapy improves survival rates but incurs significant costs for neonatal intensive care services.
- Understanding the economic implications of surfactant use is crucial for resource allocation.
Purpose of the Study:
- To assess the cost-effectiveness of different surfactant administration policies for preterm neonates.
- To evaluate the economic impact of surfactant use in relation to infant survival and gestational age.
- To inform optimal clinical and economic strategies for surfactant therapy.
Main Methods:
- Utilized evidence on resource utilization from randomized controlled trials of surfactant therapy.
- Incorporated data from economic studies on the costs associated with surfactant use.
- Conducted cost-effectiveness analyses for various surfactant administration strategies (prophylactic vs. treatment, dosage variations).
Main Results:
- For the smallest preterm infants, surfactant therapy is projected to increase overall neonatal care costs.
- Despite increased costs, surfactant use is likely to improve the cost-to-survival ratio for these infants.
- The optimal surfactant policy for infants over 31 weeks' gestation remains less clear and is under investigation.
Conclusions:
- Surfactant therapy is a cost-effective intervention for the smallest preterm infants with RDS, enhancing survival.
- Ongoing multicenter trials are comparing prophylactic versus later treatment and different dosage regimens.
- Surfactant policies should be integrated with obstetric interventions that reduce the incidence of RDS.
Abstract:
Surfactant replacement in preterm babies has been shown in recent years in randomised controlled trials to be an effective treatment for respiratory distress syndrome (RDS). It is expensive and, because it increases survival, it has implications for the costs of neonatal services. We used evidence about resource use obtained from trials of surfactant and other studies on the economics of surfactant to assess the cost effectiveness of different policies for its use. For the smallest babies, surfactant is likely to increase overall costs of neonatal care, but also to reduce the ratio of costs to survival, whether surfactant is given prophylactically or as a treatment for established RDS. It is less clear what the optimal policy should be for babies of more than around 31 weeks' gestation. Comparison of the relative cost effectiveness of policies of early prophylactic surfactant and surfactant for later treatment of RDS, and of different dosage policies, is currently being conducted in the context of 2 large multicentre trials. No policy for surfactant use should be considered in isolation from the availability of effective obstetric interventions which have been shown to reduce the risk of RDS in preterm babies and which will therefore reduce the need for surfactant.